Luspatercept vs. Epoetin Alfa for the treatment of Anemia due to Low-Risk MDS

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The “ELEMENT-MDS” Trial

Disease Types: Hematology

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The “ELEMENT-MDS” Trial

For More Information:

https://clinicaltrials.gov/study/NCT05949684?term=A%20Phase%203,%20Open-label,%20Randomized%20Study%20to%20Compare%20the%20Efficacy%20and%20Safety%20of%20Luspatercept%20(ACE-536)%20vs%20Epoetin%20Alfa%20for%20the%20Treatment%20of%20Anemia%20Due%20to%20Revised%20International%20Prognostic%20Scoring%20System%20(IPSS-R)%20Very%20Low,%20Low,%20or%20Intermediate-Risk%20Myelodysplastic%20Syndrome%20(MDS)%20in%20Erythropoiesis-Stimulating%20Agent%20(ESA)-naive%20Participants%20who%20are%20Non-Transfusion%20Dependent%20(NTD):%20The%20%E2%80%9CELEMENT-MDS%E2%80%9D%20Trial&rank=1